Back to Search
Start Over
Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease
- Source :
- Annals of Neurology, Annals of Neurology, 2021, 90 (1), pp.62-75. ⟨10.1002/ana.26085⟩
- Publication Year :
- 2021
- Publisher :
- John Wiley & Sons, Inc., 2021.
-
Abstract
- International audience; Objective: This multilanguage study used simple speech recording and high-end pattern analysis to provide sensitive and reliable noninvasive biomarkers of prodromal versus manifest α-synucleinopathy in patients with idiopathic rapid eye movement sleep behavior disorder (iRBD) and early-stage Parkinson disease (PD).Methods: We performed a multicenter study across the Czech, English, German, French, and Italian languages at 7 centers in Europe and North America. A total of 448 participants (337 males), including 150 with iRBD (mean duration of iRBD across language groups 0.5-3.4 years), 149 with PD (mean duration of disease across language groups 1.7-2.5 years), and 149 healthy controls were recorded; 350 of the participants completed the 12-month follow-up. We developed a fully automated acoustic quantitative assessment approach for the 7 distinctive patterns of hypokinetic dysarthria.Results: No differences in language that impacted clinical parkinsonian phenotypes were found. Compared with the controls, we found significant abnormalities of an overall acoustic speech severity measure via composite dysarthria index for both iRBD (p = 0.002) and PD (p < 0.001). However, only PD (p < 0.001) was perceptually distinct in a blinded subjective analysis. We found significant group differences between PD and controls for monopitch (p < 0.001), prolonged pauses (p < 0.001), and imprecise consonants (p = 0.03); only monopitch was able to differentiate iRBD patients from controls (p = 0.004). At the 12-month follow-up, a slight progression of overall acoustic speech impairment was noted for the iRBD (p = 0.04) and PD (p = 0.03) groups.Interpretation: Automated speech analysis might provide a useful additional biomarker of parkinsonism for the assessment of disease progression and therapeutic interventions. ANN NEUROL 2021;90:62-75.
- Subjects :
- 0301 basic medicine
Male
Disease
REM Sleep Behavior Disorder
Audiology
Behavior disorder
Dysarthria
MESH: Aged, 80 and over
0302 clinical medicine
Research Articles
MESH: Aged
Aged, 80 and over
MESH: Middle Aged
MESH: Speech
Parkinsonism
Parkinson Disease
Middle Aged
Europe
Neurology
Disease Progression
Biomarker (medicine)
MESH: Disease Progression
[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
Female
medicine.symptom
Research Article
medicine.medical_specialty
Rapid eye movement sleep
Prodromal Symptoms
REM sleep behavior disorder
03 medical and health sciences
medicine
Humans
Speech
[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
MESH: Prodromal Symptoms
Aged
MESH: Humans
business.industry
Disease progression
medicine.disease
MESH: Male
030104 developmental biology
MESH: REM Sleep Behavior Disorder
MESH: Biomarkers
MESH: Europe
Neurology (clinical)
business
MESH: Female
MESH: Parkinson Disease
030217 neurology & neurosurgery
Biomarkers
Subjects
Details
- Language :
- English
- ISSN :
- 15318249 and 03645134
- Volume :
- 90
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Annals of Neurology
- Accession number :
- edsair.doi.dedup.....7a4e0d32ec9c857edcd1a73d567a0dd8
- Full Text :
- https://doi.org/10.1002/ana.26085⟩